Drug Trial Radar · NCT01214226
Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis
Last checked: Nov 20, 2026Latest source record: Jun 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
278
Actual
Start
Dec 2007
Primary completion
Dec 2010
Study completion Jan 2011
Sponsor
- Lead sponsor
- University Hospital, LilleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France
- First posted
- Oct 4, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The treatment of severe forms of alcoholic hepatitis (AH) constitutes a major challenge for clinicians involved in the management of severe alcoholic liver disease. In patients with Maddrey function higher than 32, compelling evidence from data has shown that corticosteroids improve short-term survival. However, novel strategies or molecules are required in light of the fact that approximately 40 % of patients continue to die at 6 months. A double-blinded randomized controlled trial of 101 patients has showed that Pentoxifylline improves survival of patients with severe AH, as compared to placebo. In terms of mechanisms, the effect of pentoxifylline is related to prevention of hepatorenal function whereas corticosteroids induce an early improvement in liver function. When considering these differences of mechanisms, many clinicians suggest that the addition of pentoxyfilline to corticosteroids is an attractive option that needs to be tested in patients with severe AH.
Conditions
- Alcoholic Hepatitis
- Alcoholic Liver Disease
Interventions
PentoxifyllineDrug
400 mg prolonged-released tablets 3 time per day for 1 month.
placeboDrug
prolonged-release tablets 3 time per day for 1 month
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: 6 months
Locations
28 sites in 2 countries. Site status is shown where the registry gives one.
University hospital
Brussels, Belgium
University hospital
Angers, France
Centre hospitalier
Béthune, France
Hôpital Jean Verdier (AH-HP)
Bondy, France
University hospital
Bordeaux, France
University hospital
Caen, France
Hospital Antoine Béclère (Assistance Publique des Hôpiaux de Paris)
Clamart, France
Hôpital Beaujon (AH-HP)
Clichy, France
Centre Hospitalier
Creil, France
Hôpital Henri Mondor (AP-HP)
Créteil, France
Centre hospitalier
Dunkirk, France
Centre Hospitalier
Lens, France
University hospital
Lille, France
Centre hospitalier Sambre en avesnois
Maubeuge, France
University hospital
Montpellier, France
University hospital
Nantes, France
University hospital
Nice, France
Hôpital Saint Antoine (AP-HP)
Paris, France
Hôpital de la Pitié-Salpétrière (AP-HP)
Paris, France
Hôpital Cochin (AH-HP)
Paris, France
University hospital
Poitiers, France
University hospital
Rennes, France
Centre Hospitalier Victor Provo
Roubaix, France
University Hospital
Strasbourg, France
Centre Hospitalier
Tourcoing, France
Centre Hospitalier
Valenciennes, France
University hospital, Nancy
Vandœuvre-lès-Nancy, France
Hôpital Paul Brousse (AH-HP)
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.